Micra TPS is a leadless pacemaker for patients who only require pacing in the right ventricle. Credit: Jorge Gonzalez from Pixabay.

Medtronic has announced new data from the Micra Coverage with Evidence Development (CED) trial which demonstrated significant reduction in complications and reinterventions with the Micra Transcatheter Pacing System (TPS).

Micra TPS, with less than one-tenth the size of traditional pacemakers, is a leadless pacemaker for patients who only require pacing in the right ventricle.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The observational and cohort study evaluated the use, complications, and results of Micra TPS in the US Medicare fee-for-service population.

The trial assessed 6,219 patients implanted with Micra VR TPS and 10,212 patients implanted with traditional TV-VVI pacemakers.

Researchers compared the chronic complications, system reinterventions, as well as all-cause mortality at two-years after implanting the pacemakers.

It was found that the Micra TPS showed a 38% reduction in reinterventions and a 31% in chronic complications compared with standard TV-VVI pacemakers.

No difference was observed in adjusted all-cause mortality at two years compared to the transvenous comparator population, although Micra patients had more comorbidities than transvenous-VVI patients.

Duke University Medical Center cardiac electrophysiology director and medicine associate professor Jonathan Piccini said: “There is considerable evidence supporting the safety and efficacy of leadless pacemakers, but limited data evaluating their long-term outcomes compared to traditional pacemakers in a real-world setting.

“The results from this study further support the connection of a lower risk of complications with leadless pacing compared with traditional transvenous single chamber pacing. These data should help guide physicians as they determine the best pacing options for their patients.”

Medtronic recently announced that over 100,000 patients are using a Micra device across the world.